Market Overview

Mallinckrodt Bull Turns Bear, Slashes Price Target By 66%

Mallinckrodt Bull Turns Bear, Slashes Price Target By 66%
FDA Snubs Mallinckrodt's Abuse-Deterrent Opioid Reformulation
31 Stocks Moving In Wednesday's Pre-Market Session
Stocks To Watch: Time To Connect The Dots (Seeking Alpha)

With concerns about Acthar, which fetches Mallinckrodt PLC (NYSE: MNK) roughly one-third of its revenues, UBS tempered its expectations.

The Analyst & Rating

UBS analyst Marc Goodman downgraded shares of Mallinckrodt from Buy to Neutral and lowered its 12-month price target from $70 to $24, a 66 percent downward revision.

The Thesis

Acthar volumes could come under pressure, contrary to previous expectations that it would continue to grow, Goodman said in a note. Going by the management's recent comments on Acthar, Goodman is not as optimistic as before.

The analyst made changes to his Acthar model, estimating declining volume, even as market share and pricing assumptions were left unchanged. This along with lower INOmax sales for potential Praxair, Inc. (NYSE: PX) competition, has led the analyst to significantly reduce his valuation.

UBS is moving to the sidelines at current levels until it has more visibility on Acthar volumes, INOmax competition, generics stability and pipeline. The firm lowered its earnings per share estimates for 2017 from $7.40 to $7.15 and that for 2016 from $8.15 to $7.15, assuming among other things, a 14 percent year-over-year drop in Acthar sales.

Price Action

At time of writing, shares of Mallinckrodt were down less than 1 percent at $21.62. The stock is down 56 percent in 2017.

Related Link:

Here's Why Barclays Downgraded Mallinckrodt

Analyst: Nektar Has A Handful Of Milestones Ahead In 2018

Latest Ratings for MNK

Nov 2018Canaccord GenuityUpgradesHoldBuy
Sep 2018BerenbergInitiates Coverage OnSell
Sep 2018Goldman SachsDowngradesNeutralSell

View More Analyst Ratings for MNK
View the Latest Analyst Ratings

Posted-In: Marc Goodman UBSAnalyst Color Upgrades Price Target Top Stories Analyst Ratings Best of Benzinga


Related Articles (PX + MNK)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Stocks Going Ex Dividend The Third Week of November

Casino ETF Hits New 52-Week High